Sarah Drier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sarah Drier has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Katherine Elizabeth Reeder-Hayes
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
2 shared publications - Anagha Gogate
WWHEOR, Bristol Myers Squibb, Princeton, NJ, United States
1 shared publication - Austin R. Waters
Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
1 shared publication - Charlotte Ellis
Department of Health Policy and Management, UNC Gillings School of Global Public Health, Chapel Hill, USA
1 shared publication Donatus U Ekwueme
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA
1 shared publicationJennifer C. Spencer
Department of Population Health, Dell Medical School, University of Texas at Austin, Austin, USA
1 shared publication
Latest Publications
- Open Access
- 23 August 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (9) , 1-8
Impact of motivational interviewing on psychosocial and symptom outcomes during breast cancer endocrine therapy
Purpose: Adjuvant endocrine therapy (ET) is recommended to women with hormone receptor-positive (HR +) breast cancer for 5–10 years to reduce recurrence risk and mortality, but adhering to ET for this full period is challenging due to the physical and psychosocial effects of treatment. We sought to understand how participation in a patient-centered counseling intervention affected anxiety and depression, recurrence worry, and treatment related symptoms. Methods: We conducted a single-arm pilot study over a 12-month period, consisting of five counselor-led motivational interviewing (MI) counseling sessions. Eligible participants were over 18 years old, English speaking, and had stage I-III HR + breast cancer. Survey data collected at baseline and 12 months assessed anxiety and depression, and cancer recurrence worry. Endocrine symptoms were assessed at the 12-month time point, reported descriptively, and age-stratified to examine if symptom burden and age were related. Results: Of the 42 women who initiated the intervention, 35 completed the baseline and 12-month surveys. Most participants were over 50 (63%), non-Black and non-Hispanic (63%; 97%). Overall patient-reported anxiety and depression decreased from baseline to 12 months, though only the change in anxiety was statistically significant, while cancer worry increased slightly. The most reported endocrine symptoms were hot flashes, night sweats, vaginal dryness, disinterest in sex, and joint pain; endocrine symptoms did not vary by age. Conclusion: This study shows early promise in the efficacy of MI to improve anxiety, depression, recurrence worry, and treatment-related endocrine symptoms.
- 23 August 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (9) , 1-8
Open AccessImpact of motivational interviewing on psychosocial and symptom outcomes during breast cancer endocrine therapy
Purpose: Adjuvant endocrine therapy (ET) is recommended to women with hormone receptor-positive (HR +) breast cancer for 5–10 years to reduce recurrence risk and mortality, but adhering to ET for this full period is challenging due to the physical and psychosocial effects of treatment. We sought to understand how participation in a patient-centered counseling intervention affected anxiety and depression, recurrence worry, and treatment related symptoms. Methods: We conducted a single-arm pilot study over a 12-month period, consisting of five counselor-led motivational interviewing (MI) counseling sessions. Eligible participants were over 18 years old, English speaking, and had stage I-III HR + breast cancer. Survey data collected at baseline and 12 months assessed anxiety and depression, and cancer recurrence worry. Endocrine symptoms were assessed at the 12-month time point, reported descriptively, and age-stratified to examine if symptom burden and age were related. Results: Of the 42 women who initiated the intervention, 35 completed the baseline and 12-month surveys. Most participants were over 50 (63%), non-Black and non-Hispanic (63%; 97%). Overall patient-reported anxiety and depression decreased from baseline to 12 months, though only the change in anxiety was statistically significant, while cancer worry increased slightly. The most reported endocrine symptoms were hot flashes, night sweats, vaginal dryness, disinterest in sex, and joint pain; endocrine symptoms did not vary by age. Conclusion: This study shows early promise in the efficacy of MI to improve anxiety, depression, recurrence worry, and treatment-related endocrine symptoms.
- Open Access
- 6 July 2021
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (4)
Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030
Background: This study projected the number of metastatic breast cancer (mBC) cases and costs (medical and productivity) attributable to mBC through 2030 among 3 age groups: younger (aged 18-44 years), midlife (aged 45-64 years), and older women (aged 65 years and older). Methods: We developed a stock/flow model in which women enter the mBC population at initial diagnosis (de novo stage IV) or through progression of an earlier-stage cancer. Women exit the mBC population through death. Input parameters by age and phase of treatment came from the US Census, Surveillance, Epidemiology, and End Results and peer-reviewed literature. Results: In 2030, we estimated there would be 246 194 prevalent cases of mBC, an increase of 54.8% from the 2015 estimate of 158 997. We estimated total costs (medical and productivity) of mBC across all age groups and phases of care were $63.4 billion (95% sensitivity range = $59.4-$67.4 billion) in 2015 and would increase to $152.4 billion (95% sensitivity range = $111.6-$220.4 billion) in 2030, an increase of 140%. Trends in estimated costs were higher for younger and midlife women than for older women. Conclusions: The cost of mBC could increase substantially in the coming decade, especially among younger and midlife women. Although accounting for trends in incidence, progression, and survival, our model did not attempt to forecast structural changes such as technological innovations in breast cancer treatment and health-care delivery reforms. These findings can motivate early detection activities, direct value-driven mBC treatment, and provide a useful baseline against which to measure the effect of prevention and treatment efforts.
- 6 July 2021
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (4)
Open AccessProjecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030
Background: This study projected the number of metastatic breast cancer (mBC) cases and costs (medical and productivity) attributable to mBC through 2030 among 3 age groups: younger (aged 18-44 years), midlife (aged 45-64 years), and older women (aged 65 years and older). Methods: We developed a stock/flow model in which women enter the mBC population at initial diagnosis (de novo stage IV) or through progression of an earlier-stage cancer. Women exit the mBC population through death. Input parameters by age and phase of treatment came from the US Census, Surveillance, Epidemiology, and End Results and peer-reviewed literature. Results: In 2030, we estimated there would be 246 194 prevalent cases of mBC, an increase of 54.8% from the 2015 estimate of 158 997. We estimated total costs (medical and productivity) of mBC across all age groups and phases of care were $63.4 billion (95% sensitivity range = $59.4-$67.4 billion) in 2015 and would increase to $152.4 billion (95% sensitivity range = $111.6-$220.4 billion) in 2030, an increase of 140%. Trends in estimated costs were higher for younger and midlife women than for older women. Conclusions: The cost of mBC could increase substantially in the coming decade, especially among younger and midlife women. Although accounting for trends in incidence, progression, and survival, our model did not attempt to forecast structural changes such as technological innovations in breast cancer treatment and health-care delivery reforms. These findings can motivate early detection activities, direct value-driven mBC treatment, and provide a useful baseline against which to measure the effect of prevention and treatment efforts.